Aileron Therapeutics Inc. (ALRN)
undefined
undefined%
At close: undefined
2.25
-1.32%
After-hours Dec 13, 2024, 05:42 PM EST

Company Description

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States.

The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.

It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC.

The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007.

Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.

Aileron Therapeutics Inc.
Aileron Therapeutics Inc. logo
Country United States
IPO Date Jun 29, 2017
Industry Biotechnology
Sector Healthcare
Employees 15
CEO Dr. James Brian Windsor Ph.D.

Contact Details

Address:
285 Summer Street
Boston, Massachusetts
United States
Website https://www.aileronrx.com

Stock Details

Ticker Symbol ALRN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001420565
CUSIP Number 00887A105
ISIN Number US00887A2042
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Dr. James Brian Windsor Ph.D. Chief Executive Officer, President & Director
Timothy M. Cunningham CPA, M.B.A. Interim Chief Financial Officer & Principal Accounting Officer

Latest SEC Filings

Date Type Title
Dec 09, 2024 4 Filing
Dec 06, 2024 4 Filing
Dec 06, 2024 4 Filing
Dec 06, 2024 4 Filing
Dec 06, 2024 4 Filing
Dec 06, 2024 4 Filing
Dec 04, 2024 4 Filing
Nov 14, 2024 8-K Current Report
Nov 14, 2024 10-Q Quarterly Report
Nov 05, 2024 SCHEDULE 13G/A [Amend] Filing